
Wichtige Hürde für das Medikament zur Gewichtskontrolle und Typ-2-Diabetes genommen
AI-generated summary
Eli Lilly hat eine Empfehlung der EMA zur Zulassung der Abnehmpille Foundayo erhalten.
Berlin. Der US-Pharmakonzern Eli Lilly hat für seine Abnehmpille Foundayo eine wichtige Hürde auf dem Weg zur Zulassung in der Europäischen Union genommen. Ein Ausschuss der EU-Arzneimittelbehörde EMA empfahl am Freitag die Zulassung des Medikaments zur Gewichtskontrolle und zur Behandlung von Typ-2-Diabetes bei Erwachsenen.
Die EU-Kommission muss der Empfehlung nun noch zustimmen, bevor Eli Lilly das Mittel auf den Markt bringen kann. Foundayo wäre nach der Pille Wegovy des dänischen Rivalen Novo Nordisk das zweite orale Medikament dieser Art mit einer Zulassung in der EU.
AI outlook — possibilities, not facts
EU-Kommission stimmt der Zulassung zu
Likely · Within months

Due to the impending shortage of general practitioners in Germany and Brandenburg, the Medical University of Lausitz has started operations in Cottbus with its first students. A new country doctor quota should provide long-term relief.

In the Malteser practice in Stuttgart, more and more people without health insurance are seeking medical help. In addition to refugees and homeless people, pensioners and self-employed people who fell out of the system due to contribution debts are increasingly affected.
A study published in the journal Nature Medicine describes menopause as a “physiological cliff.” Researchers evaluated 300 million laboratory data and found that metabolism, organ functions and hormones were already changing abruptly years before.

Former Olympic sprinter Beth Dobbin suffers from the chronic multisystem disease ME/CFS. She reports on the severity of the symptoms, the lack of recognition of the disease and the lack of effective treatment options.

Health economist Boris Augurzky criticizes the contribution rate stabilization law as a short-term shift in burdens to the detriment of hospitals and calls for structural reforms, reductions in bureaucracy and a sensible approach to the sugar tax.

The CEO of the National Association of Statutory Health Insurance Funds, Oliver Blatt, calls for a fairer allocation of doctor's appointments based on medical needs instead of insurance status. He criticizes the current disadvantage of the 75 million people with statutory health insurance as 'blazing injustice' and rejects the term two-class medicine, while proposing a daily platform for making appointments.